CN114774359B - Cervical squamous carcinoma organoid culture medium and construction method thereof - Google Patents
Cervical squamous carcinoma organoid culture medium and construction method thereof Download PDFInfo
- Publication number
- CN114774359B CN114774359B CN202210298185.3A CN202210298185A CN114774359B CN 114774359 B CN114774359 B CN 114774359B CN 202210298185 A CN202210298185 A CN 202210298185A CN 114774359 B CN114774359 B CN 114774359B
- Authority
- CN
- China
- Prior art keywords
- squamous carcinoma
- cervical squamous
- organoid
- cervical
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002220 organoid Anatomy 0.000 title claims abstract description 118
- 206010041823 squamous cell carcinoma Diseases 0.000 title claims abstract description 87
- 239000001963 growth medium Substances 0.000 title claims abstract description 64
- 238000010276 construction Methods 0.000 title claims abstract description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 34
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims abstract description 28
- 210000001519 tissue Anatomy 0.000 claims abstract description 22
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 17
- 102000045246 noggin Human genes 0.000 claims abstract description 16
- 108700007229 noggin Proteins 0.000 claims abstract description 16
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 15
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 claims abstract description 15
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 15
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims abstract description 14
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000020939 nutritional additive Nutrition 0.000 claims abstract description 14
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims abstract description 13
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims abstract description 13
- 229930182555 Penicillin Natural products 0.000 claims abstract description 12
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 12
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 claims abstract description 12
- 229940049954 penicillin Drugs 0.000 claims abstract description 12
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 claims abstract description 11
- 208000019065 cervical carcinoma Diseases 0.000 claims abstract description 9
- 239000007995 HEPES buffer Substances 0.000 claims abstract description 7
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 30
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 20
- 238000012258 culturing Methods 0.000 claims description 16
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 14
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 14
- 201000010881 cervical cancer Diseases 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 11
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 9
- 239000012574 advanced DMEM Substances 0.000 claims description 8
- 239000007640 basal medium Substances 0.000 claims description 7
- 108010082117 matrigel Proteins 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 238000012423 maintenance Methods 0.000 abstract description 6
- 230000002068 genetic effect Effects 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000000052 comparative effect Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 14
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 13
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- KRGPXXHMOXVMMM-UHFFFAOYSA-N nicotianamine Natural products OC(=O)C(N)CCNC(C(O)=O)CCN1CCC1C(O)=O KRGPXXHMOXVMMM-UHFFFAOYSA-N 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 3
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 3
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 3
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 3
- 102100022762 R-spondin-1 Human genes 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FSILHPZFNRDTOR-RZVRUWJTSA-N (2R)-2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)N[C@@H](CS)C(O)=O.CC(=O)N[C@@H](CS)C(O)=O FSILHPZFNRDTOR-RZVRUWJTSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000002133 sample digestion Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of organoid culture, and particularly discloses a cervical squamous carcinoma organoid culture medium and a construction method thereof. The cervical squamous carcinoma organoid culture medium comprises the following components: a basal culture medium, an HEPES buffer pair, a penicillin streptomycin solution, a nutritional additive and a specific factor; the specific factors comprise nicotinamide, N-acetylcysteine, Y-27632, noggin factor, A83-01, EGF, FGF10, forskolin and hydrocortisone. The invention develops the cervical squamous carcinoma organoid culture medium aiming at cervical squamous carcinoma, improves the culture success rate and long-term maintenance rate of the cervical carcinoma organoid, and the cultured cervical squamous carcinoma organoid can maintain the histological morphology and genetic characteristics of original tumor tissues; the developed cervical squamous carcinoma organoid culture medium is beneficial to providing a new idea for the research of cervical carcinoma.
Description
Technical Field
The invention relates to the technical field of organoid culture, in particular to a cervical squamous carcinoma organoid culture medium and a construction method thereof.
Background
Cervical cancer is one of the most common gynecological tumors. 2021 global statistical analysis of tumors suggested that the incidence and mortality of cervical cancer were the fourth of all gynecological tumors. The most common types of pathology for cervical cancer are squamous cell carcinoma and adenocarcinoma, accounting for 70% and 25% of all cases, respectively. Squamous carcinomas originate in cervical squamous epithelia and adenocarcinomas in columnar epithelia. To date, cervical cancer research has relied on a limited number of cell lines, xenografts, and transgenic mouse models. Widely used cell lines such as hela, siha have been partially deprived of generalisation of clinical patient characteristics and have limited preclinical research value through long-term in vitro culture selection. However, the xenograft and transgenic models cannot be widely applied in research due to high price, long culture period and the like. Therefore, we established an economical and simple model representative of patients for the study of cervical cancer.
Cancer research relies on a stable supply of cells-normal and cancerous cells that can be cultured in the laboratory. The tumor organoid is an in vitro 3D culture model developed in recent years, the model simulates extracellular matrix by using materials such as matrigel or hydrogel and the like in vitro, provides a three-dimensional bracket for cells, exogenously adds substances such as small molecules, growth factors and the like to form a stem cell ecological environment, induces self-renewal and differentiation of tissues or stem cells to form a three-dimensional cell structure, and the organoid model is closely related to source tissues and reproduces the cell structure and genetic traits of the source tissues. The genetic heterogeneity and biological characteristics of the patient tumor can be well reproduced in vitro by constructing the tumor organoids derived from the patient, and the patient individualized treatment scheme can be guided by performing high-throughput drug screening on the organoids by combining next generation sequencing. In the research of tumor mechanism, organoid model can be used as supplement between cell experiment and in vivo experiment, and organoid from patient can be used as bridge between animal model and human clinical experiment.
However, the existing culture success rate for culturing the cervical squamous cell carcinoma organoid in the prior art is low, and only has a success rate of 50%, so that a cervical squamous cell carcinoma organoid culture medium with high culture success rate is needed.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a cervical squamous carcinoma organoid culture medium and a construction method thereof. The cervical squamous carcinoma organoid culture medium developed aiming at cervical squamous carcinoma can improve the success rate and long-term maintenance rate of cervical carcinoma organoid culture, and is favorable for providing a new idea for cervical carcinoma research.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention provides a cervical squamous carcinoma organoid culture medium, which comprises the following components:
a basal culture medium, a HEPES buffer pair, a penicillin streptomycin solution, a nutritional additive and a specific factor;
the specific factor is nicotinamide, N-acetylcysteine, Y-27632, noggin factor, A83-01, EGF, FGF10, forskolin and hydrocortisone.
Through a large amount of researches and experiments, the inventor of the invention discovers that a culture medium for the cervical squamous carcinoma organoid is developed, the culture success rate and the long-term maintenance rate of the cervical squamous carcinoma organoid are improved, the culture success rate of the cervical squamous carcinoma organoid is improved from 50% to 73%, the biological activity of the cervical squamous carcinoma organoid is well maintained, the growth activity and the morphology of the organoid are not influenced, and the cultured cervical squamous carcinoma organoid can maintain the histological morphology and the genetic characteristics of the original tumor tissue.
Wherein, the addition of HEPES buffer to the culture medium can promote the biological activity of organoid and prevent the adverse effect of pH fluctuation of the culture medium on the cell growth. The specific factors can be added to synergistically improve the culture success rate of cervical squamous carcinoma organoids.
As a preferred embodiment of the cervical squamous carcinoma organoid culture medium of the invention, the cervical squamous carcinoma organoid culture medium comprises the following components:
basic culture medium, HEPES buffer pair 10-12 mM, penicillin streptomycin solution 1-2%, nutrient additive 1-3%, nicotinamide 10-12 mmol/L, N-acetylcysteine 1-1.5 mmol/L, Y-27632 2-10 mu M, noggin factor 80-120 ng/ml, A83-01-450 nmol/L, EGF-10 ng/ml, FGF 10-120 ng/ml, forskolin 8-12 mu M and hydrocortisone 400-600 ng/ml.
As a preferred embodiment of the cervical squamous carcinoma organoid culture medium of the invention, the cervical squamous carcinoma organoid culture medium comprises the following components:
basal medium, HEPES buffer pair 10mM, penicillin streptomycin solution 1%, nutritional supplement 3%, nicotinamide 10mmol/L, N-acetylcysteine 1.25mmol/L, Y-27632 10. Mu. M, noggin factor 100ng/ml, A83-01 500nmol/L, EGF ng/ml, FGF10 100ng/ml, forskolin 10. Mu.M and hydrocortisone 500ng/ml.
As a preferred embodiment of the cervical squamous carcinoma organoid culture medium, the basic culture medium is advanced DMEM/F12; the nutritional additive is at least one of Glutamax, B27 and N2. More preferably, the nutritional additive is a combination of Glutamax, B27 and N2. The addition of the nutrient is beneficial to the culture of the cervical squamous carcinoma organoid, so that the growth form of the cervical squamous carcinoma organoid is better.
As a preferred embodiment of the cervical squamous carcinoma organoid culture medium, the volume ratio of the nutritional additive to the specific factor is 10: (0.5-1.5). More preferably, the volume ratio of the nutritional supplement to the specific factor is 10:0.8.
when the nutrient additive and the specific factor are compounded in a specific volume ratio, the culture effect of the cervical squamous carcinoma organoid can be improved.
The invention provides a method for constructing a cervical squamous carcinoma organoid model, which comprises the following steps:
1) Obtaining cervical cancer tissues, mechanically and enzymatically digesting the cervical cancer tissues, filtering and centrifuging, retaining cell precipitates, and removing red blood cells to obtain cell masses;
2) Resuspending the cell pellet in matrigel, inoculating, and fixing; culturing in the above-mentioned cervical squamous carcinoma organoid culture medium, observing and changing liquid every 2-3 days, and subculturing every 7-21 days.
As a preferred embodiment of the method for constructing the organoid model of cervical squamous carcinoma of the present invention, in step 1), the cervical cancer tissue is digested with collagenase II at a concentration of 0.5 mg/ml.
As a preferred embodiment of the method for constructing the organoid model of cervical squamous carcinoma of the present invention, in step 2), the cell mass is resuspended in matrigel at a density of 1 ten thousand cells/10. Mu.l.
In a third object, the invention provides the use of the culture medium in culturing cervical squamous carcinoma organoids.
Compared with the prior art, the invention has the following beneficial effects:
the invention develops the cervical squamous carcinoma organoid culture medium aiming at cervical squamous carcinoma, improves the culture success rate and the maintenance rate after passage of the cervical carcinoma organoid, and the cultured cervical squamous carcinoma organoid can maintain the histological morphology and the genetic characteristics of the original tumor tissue; the developed cervical squamous carcinoma organoid culture medium is beneficial to providing a new idea for the research of cervical carcinoma.
Drawings
FIG. 1 is a light microscopic image of a cervical squamous carcinoma organoid obtained after culture in the cervical squamous carcinoma organoid culture medium of example 1;
FIG. 2 is a light microscopic image of a cervical squamous carcinoma organoid obtained after culture in the cervical squamous carcinoma organoid culture medium of example 2;
FIG. 3 is a comparative statistical plot of the effect of the cervical squamous carcinoma organoid culture media of example 2 and comparative examples 1-12 on cervical squamous carcinoma organoid size;
fig. 4 is an optical microscope photograph of cervical squamous carcinoma organoids obtained after culture in the cervical squamous carcinoma organoid culture medium of comparative example 13.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.
In the following examples and comparative examples, the experimental methods used were all conventional ones unless otherwise specified, and the materials, reagents and the like used were commercially available.
In the following examples and comparative examples, the nutritional additives include Glutamax, B27 and N2; the specific factor is nicotinamide, N-acetylcysteine, Y-27632, noggin factor, A83-01, EGF, FGF10, forskolin and hydrocortisone.
In the following examples and comparative examples, penicillin streptomycin solution (100 Xpenicillin streptomycin mixed solution), hepes buffer pair, glutamax, B27, N2 were purchased from England Weiji (Shanghai) trade Co., ltd.; nicotinamide (nicotinamide), N-acetylcysteine (N-acetylcysteine), forskolin, A83-01, available from Sigma-Aldrich; noggin factor, EGF, FGF10, R-spondin 1, CHIR99021 from PeproTech; y-27632, hydrocortisone (Hydrocortisone) was purchased from stem cell.
Example 1 cervical squamous carcinoma organoid culture Medium
This example provides a cervical squamous carcinoma organoid culture medium comprising the basal medium Advanced DMEM/F12, 12mM Hepes buffer pair, 2% penicillin streptomycin solution, 1% Glutamax, 1% B27, 1% N2, 12mmol/L nicotinamide (nicotinamine), 1.25mmol/L N-acetylcysteine (N-acetylcysteine), 2 μ M Y-27632, 100ng/ml Noggin factor, 500nmol/L A-83-01, 10ng/ml EGF, 100ng/ml FGF10, 10 μ M Forskolin, and 500ng/ml hydrocortisone. The concentration of each component of the specific factor is based on the concentration of the specific factor in the culture medium of the cervical squamous carcinoma organoid.
Wherein, the volume ratio of the nutritional additive to the specific factor is 10:0.8.
example 2 cervical squamous carcinoma organoid culture Medium
This example provides a cervical squamous carcinoma organoid medium comprising the basal medium Advanced DMEM/F12, 10mM Hepes buffer pair, 1% penicillin streptomycin solution, 1% Glutamax, 1% B27, 1% N2, 10mmol/L nicotinamide (nicotinamine), 1.25mmol/L N-acetylcysteine (N-acetylcysteine), 10 μ M Y-27632, 100ng/ml Noggin factor, 500nmol/L A-01, 5ng/ml EGF, 100ng/ml FGF10, 10 μ M Forskolin, and 500ng/ml hydrocortisone. The concentration of each component of the specific factor is based on the concentration of the specific factor in the culture medium of the cervical squamous carcinoma organoid.
Wherein, the volume ratio of the nutritional additive to the specific factor is 10:0.5.
example 3 cervical squamous carcinoma organoid culture Medium
This example provides a cervical squamous carcinoma organoid culture medium comprising the basal medium Advanced DMEM/F12, 10mM Hepes buffer pair, 1% penicillin streptomycin solution, 0.3% Glutamax, 0.3% B27, 0.4% N2, 10mmol/L nicotinamide (nicotinamine), 1.0mmol/L N-acetylcysteine (N-acetylcysteine), 5 μ M Y-27632, 80ng/ml Noggin factor, 450nmol/L A-01, 5ng/ml EGF, 80ng/ml FGF10, 8 μ M skForolin, and 400ng/ml hydrocortisone. The concentration of each component of the specific factor is based on the concentration of the specific factor in the culture medium of the cervical squamous carcinoma organoid.
Wherein, the volume ratio of the nutritional additive to the specific factor is 10:1.5.
example 4 cervical squamous carcinoma organoid culture Medium
This example provides a cervical squamous carcinoma organoid medium comprising the basal medium Advanced DMEM/F12, 10mM Hepes buffer pair, 1% penicillin streptomycin solution, 1% Glutamax, 1% B27, 1% N2, 10mmol/L nicotinamide (nicotinamine), 1.5mmol/L N-acetylcysteine (N-acetylcysteine), 10 μ M Y-27632, 120ng/ml Noggin factor, 550nmol/L A-83-01, 10ng/ml EGF, 120ng/ml FGF10, 12 μ M Forskolin, and 600ng/ml hydrocortisone. The concentration of each component of the specific factor is based on the concentration of the specific factor in the culture medium of the cervical squamous carcinoma organoid.
Wherein, the volume ratio of the nutritional additive to the specific factor is 10:0.8.
A construction method of a cervical squamous carcinoma organoid model comprises the following steps:
1) Sample pretreatment: washing the cervical cancer tissue specimen obtained by resection/biopsy for 3-5 times by using normal saline to remove surface impurities, filling the cervical cancer tissue specimen into an Advanced DMEM/F12 culture medium containing 2% of double-antibody amphotericin B for preservation, and transporting the cervical cancer tissue specimen on ice;
2) Sample digestion: in a biosafety cabinet, the samples were transferred to 10cm sterile petri dishes and 1ml of 0.5mg/ml collagenase II (digest, substrate: advanced DMEM/F12 medium with 2% diabase and amphotericin B) was added and the tissue was minced to 1-5mm with sterile ophthalmic scissors 3 Transferring the tissue blocks and the digestive juice into a 50ml centrifuge tube, supplementing the digestive juice according to a proper amount of tissue volume, and carrying out shake digestion at 37 ℃ and 120rpm for 120mins;
3) Sample dissociation: terminating digestion with PBS of the same volume, filtering the digested tissue suspension with a cell sieve of 100 μm, collecting the unfiltered tissue fragments on the cell sieve, placing the unfiltered tissue fragments in a 50ml centrifuge tube, adding 3ml of tryple (plus or minus according to the number of fragments), digesting for 10mins at 37 ℃ and 120rpm by shaking;
4) Cell filtration: terminating digestion by PBS with the same volume, filtering the digested tissue suspension by a 100-micron cell sieve again, collecting filtrate obtained by filtering twice, centrifuging for 5min at 4-600 g, and retaining cell precipitate to remove supernatant;
5) Lysed erythrocytes (optional): mixing red blood cells in the visible cell precipitate, adding 1-2ml of red blood cell lysate, resuspending the cells, and lysing for 2min at room temperature;
6) Cell washing: terminating the lysis by using 10ml of PBS, centrifuging for 5min at 4-600 g, retaining cell sediment, removing supernatant, and repeating twice;
7) Inoculation: re-suspending the cell precipitate with organoid culture medium and matrigel (1:2 in volume ratio) at a density of 1 ten thousand cells/10 mul, inoculating 30 mul/well into a 48-well plate, carefully inverting the plate, fixing for 30mins in a 37-degree incubator, and adding 200ul culture medium to cover the gel drop after the gel is solidified;
8) Culturing: culturing in the above-described cervical squamous carcinoma organoid medium of examples 1-4 at 37 ℃ and 5% CO 2 The concentration is observed every 2-3 days, and the liquid is changed every 7-21 days for passage.
Cervical squamous carcinoma organoids obtained after culturing in the cervical squamous carcinoma organoid culture medium of example 1-2 above were observed under an inverted light microscope according to the construction method of example 5, as shown in fig. 1-2. The morphology of the cervical squamous carcinoma organoid obtained after the culture in the cervical squamous carcinoma organoid culture medium of examples 3-4 under an inverted light microscope is similar to that of the cervical squamous carcinoma organoid shown in FIGS. 1-2, and therefore, the description thereof is omitted.
Comparative examples 1 to 12
On the basis of example 2, comparative examples 1 to 12 show that the culture medium for the cervical squamous cell carcinoma organoid is prepared by subtracting or adding the specific factors shown in Table 1, and then the cervical squamous cell carcinoma organoid is cultured for 7 days according to the construction method of the cervical squamous cell carcinoma organoid model shown in example 5, and then 5 visual fields are randomly selected under an inverted microscope for measuring the diameter of the organoid.
TABLE 1
The effect of the cervical squamous carcinoma organoid medium of comparative examples 1-12 on cervical squamous carcinoma organoid formation is shown in FIG. 3, wherein "-" in FIG. 3 represents the medium of comparative example 2 minus the corresponding factor and "+" represents the medium of comparative example 2 plus the corresponding factor.
The results show that the diameters of the cervical squamous carcinoma organoids cultured by the cervical squamous carcinoma organoid culture medium of the comparative examples 1-12 are less than the culture effect of the cervical squamous carcinoma organoid culture medium of the example 2, wherein one of Noggin, A83-01, EGF, FGF7, FGF10, N-acetylcysteine, nicotinamide, hydrocortisone, forskolin and Y-27632 is removed from the comparative examples 1-3 and 5-10 respectively, and the culture effect of the cervical squamous carcinoma organoids is less than that of the example 2, which shows that the Noggin, A83-01, EGF, FGF7, FGF10, N-acetylcysteine, nicotinamide, hydrocortisone, forskolin and Y-27632 cooperate with each other to promote the culture effect of the cervical squamous carcinoma organoids and improve the success rate of culturing the cervical carcinoma organoids. The culture medium of comparative example 4 is added with FGF7 factor, the culture medium of comparative example 11 is added with R-spondin 1, the culture medium of comparative example 12 is added with R-spondin 1 and CHIR99021, the sizes of the cervical squamous cell carcinoma organoids after being cultured by the three culture media are smaller than those of example 2, and the technical effect of the invention can be obtained without adding any specific factor.
At the same time, the maintenance rate after passage of organoids in the culture medium of each example (the organoids are digested again into single cell suspension and planted in matrigel, the successful passage is defined when the single cells grow into organoids again, and the long-term maintenance is defined as the organoids are cultured for more than 10 generations) is observed, and all the comparative examples except examples 1 to 4 and comparative example 12 can not pass through 3 generations.
The inventor finally obtains the cervical squamous carcinoma organoid culture medium through a large number of experimental verifications, which comprises the following components: 10-12 mM of basal culture medium, 10-12 mM of Hepes buffer pair, 1-2% of penicillin streptomycin solution, 1-3% of nutritional additive, 10-12 mmol/L, N-acetylcysteine 1-1.5 mmol/L, Y-27632 0-10 mu M, noggin factor 80-120 ng/ml, A83-01-450 nmol/L, EGF-10 ng/ml, FGF 10-120 ng/ml, forskolin 8-12 mu M and hydrocortisone 400-600 ng/ml.
Comparative example 13
Compared with example 2, the volume ratio of the nutritional supplement to the specific factor is 10:3, the remaining components and concentrations were the same as in example 2, with reference to fig. 4.
Test example, effect of Cervix squamous cell carcinoma organoid culture Medium on Cervix squamous cell carcinoma culture success ratio
The groups (examples 1-4 and comparative examples 11-13) of the experimental example incorporate 60 cervical squamous carcinoma organoid samples, and the activity of the cervical squamous carcinoma organoids obtained by the culture of the cervical squamous carcinoma organoid culture medium of the above examples 1-4 and comparative examples 11-13 is detected according to the construction method of example 5, and the success rate of culturing the cervical carcinoma organoids of each group is shown in table 2, wherein successful culture means that the tumor cells or cell clusters digested under specific culture conditions can form a three-dimensional structure in vitro, i.e. organoid culture is successful.
TABLE 2
| Group of | Success rate of cervical cancer organoid culture (%) |
| Example 1 | 67％ |
| Example 2 | 73％ |
| Example 3 | 63％ |
| Example 4 | 58％ |
From the above results, it can be seen that 44 cases of cervical squamous cell carcinoma organoids obtained by culturing with the cervical squamous cell carcinoma organoid medium of example 2 can be successfully obtained, the success rate can be increased to 73% (44/60), and the effect of examples 1, 3-4 on successfully culturing cervical squamous cell carcinoma organoids is similar to that of example 2.
The culture medium of comparative examples 11-12 is newly added with other specific factors, which have a lower effect of culturing the cervical squamous carcinoma organoids than that of example 2, and shows that the specific factors are not added randomly, and the addition of some specific factors can influence the organoid culturing effect.
The culture medium of comparative example 13 changes the volume ratio of the nutrient additive and the specific factor, the success rate of culturing the cervical squamous cell carcinoma organoid is lower than that of example 2, and the fact that the nutrient additive and the specific factor are matched in a specific volume ratio can improve the success rate of culturing the cervical squamous cell carcinoma organoid.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (7)
1. The cervical squamous carcinoma organoid culture medium is characterized by comprising the following components:
a basal culture medium, a HEPES buffer pair of 10-12 mM, a penicillin streptomycin solution of 1-2%, a nutritional additive of 1-3%, nicotinamide of 10-12 mmol/L, N-acetylcysteine of 1-1.5 mmol/L, Y-27632 of 2-10 mu. M, noggin factor of 80-120 ng/ml, A83-01-450 nmol/L, EGF of 5-10 ng/ml, FGF of 10-120 ng/ml, forskolin of 8-12 mu M and hydrocortisone of 400-600 ng/ml; the nutritional additive is at least one of Glutamax, B27 and N2; nicotinamide, N-acetylcysteine, Y-27632, noggin factor, A83-01, EGF, FGF10, forskolin and hydrocortisone are used as specific factors;
the volume ratio of the nutritional additive to the specific factor is 10: (0.5-1.5).
2. The cervical squamous carcinoma organoid medium of claim 1, consisting of:
basal medium, HEPES buffered pair 10mM, penicillin streptomycin solution 1%, nutritional supplement 3%, nicotinamide 10mmol/L, N-acetylcysteine 1.25mmol/L, Y-27632 10 μ M, noggin factor 100ng/ml, A83-01 nmol/L, EGF 5ng/ml, FGF10 100ng/ml, forskolin10 μ M and hydrocortisone 500ng/ml.
3. The cervical squamous carcinoma organoid medium of claim 1, wherein said basal medium is advanced DMEM/F12.
4. A construction method of a cervical squamous carcinoma organoid model is characterized by comprising the following steps:
1) Obtaining cervical cancer tissues, mechanically and enzymatically digesting the cervical cancer tissues, filtering and centrifuging, retaining cell precipitates, and removing red blood cells to obtain cell masses;
2) Resuspending the cell pellet in matrigel, inoculating, and fixing; culturing in the cervical squamous carcinoma organoid culture medium of any of claims 1 to 3, and carrying out subculture every 7 to 21 days with fluid change observed every 2 to 3 days.
5. The method for constructing the organoid model of cervical squamous carcinoma according to claim 4, wherein in step 1), the cervical carcinoma tissue is digested with collagenase II at a concentration of 0.5 mg/ml.
6. The method of claim 4, wherein in step 2), the cell mass is resuspended in matrigel at a density of 1 ten thousand cells/10 μ l.
7. Use of the cervical squamous carcinoma organoid medium of any of claims 1 to 3 for culturing a cervical squamous carcinoma organoid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210298185.3A CN114774359B (en) | 2022-03-24 | 2022-03-24 | Cervical squamous carcinoma organoid culture medium and construction method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210298185.3A CN114774359B (en) | 2022-03-24 | 2022-03-24 | Cervical squamous carcinoma organoid culture medium and construction method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114774359A CN114774359A (en) | 2022-07-22 |
| CN114774359B true CN114774359B (en) | 2022-11-08 |
Family
ID=82424838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210298185.3A Active CN114774359B (en) | 2022-03-24 | 2022-03-24 | Cervical squamous carcinoma organoid culture medium and construction method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114774359B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115927159A (en) * | 2022-08-05 | 2023-04-07 | 复旦大学附属妇产科医院 | Preparation method of cervical cancer mixed structure cell 3D organs |
| CN116555165B (en) * | 2023-06-29 | 2024-08-06 | 重庆大学附属肿瘤医院 | Cervical cancer organoid culture medium and application thereof |
| CN118291385B (en) * | 2024-06-06 | 2024-08-23 | 成都华医再生科技有限公司 | Colorectal cancer organoid medium and colorectal cancer organoid culture method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200111168A (en) * | 2017-11-24 | 2020-09-28 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Methods and compositions for cancer treatment |
| CN111394314B (en) * | 2020-04-22 | 2020-12-01 | 创芯国际生物科技(广州)有限公司 | Culture medium and culture method for intestinal cancer organoid |
| CN112680417B (en) * | 2020-12-31 | 2024-09-17 | 汪雪 | Ovarian cancer organoid culture medium and culture method |
| CN113278588B (en) * | 2021-05-26 | 2024-01-26 | 南京市口腔医院 | Oral squamous carcinoma organoid culture medium and culture method |
-
2022
- 2022-03-24 CN CN202210298185.3A patent/CN114774359B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114774359A (en) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114774359B (en) | Cervical squamous carcinoma organoid culture medium and construction method thereof | |
| WO2023274338A1 (en) | Culture medium, method, and reagent kit for rapidly culturing tumor organoids | |
| CN114790446B (en) | Cervical adenocarcinoma organoid culture medium and construction method thereof | |
| CN111876386B (en) | Breast cancer organoid culture method and co-culture method of tumor-related fibroblasts | |
| CN111394314B (en) | Culture medium and culture method for intestinal cancer organoid | |
| CN111411083B (en) | Culture medium and culture method for stomach cancer organoid | |
| CN107208056A (en) | Original gut entoderm cell and preparation method thereof | |
| CN114292816B (en) | Lung cancer organoid culture solution, and culture reagent combination and culture method thereof | |
| CN103834613B (en) | The method for preparing multipotency angiocarpy precursor and maintaining its cardiovascular differentiation capability | |
| CN112522201A (en) | Culture medium and culture method for bladder cancer organoid | |
| Kim et al. | Isolation and culturing of glioma cancer stem cells | |
| CN111961642A (en) | Mouse liver organoid model and establishing method and application thereof | |
| CN112831471A (en) | Culture medium, culture method and detection method for thyroid cancer organoid | |
| CN113278586A (en) | Culture medium and culture method for culturing thyroid cancer organoid | |
| CN117004572A (en) | Construction method and application of patient-derived transplanted tumor organoid model PDXO | |
| Shimizu et al. | Organotypic Explant Culture of Glioblastoma Multiforme and Subsequent Single‐Cell Suspension | |
| WO2004046322A2 (en) | Replication of biological tiussue | |
| CN113943755A (en) | Method for constructing in-situ primary esophageal cancer animal model | |
| CN116987669A (en) | Bile duct cancer organoid culture kit and culture method | |
| CN114958753A (en) | Culture medium, culture method and identification method for tongue cancer organoid | |
| CN116536265A (en) | Special organoid culture medium for liver cancer, culture method and passage method | |
| CN116286655A (en) | Culture medium suitable for culturing multiple solid tumor organoids and culture method thereof | |
| EP2739971A1 (en) | In vitro tumor metastasis model | |
| CN112608899B (en) | Application of serum-free culture medium in culturing spheroids of cancer tissue origin | |
| CN114369573B (en) | Method for constructing in-situ primary nasopharyngeal carcinoma animal model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |